The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial.
<h4>Background</h4>Most HIV-1-infected patients on effective antiretroviral therapy (ART) with plasma HIV-1 RNA levels below the detection limits of commercial assays have residual viremia measurable by more sensitive methods. We assessed whether adding raltegravir lowered the level of r...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Public Library of Science (PLoS)
2010
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/ea37066179f74b4490ef6ff4cce51619 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:ea37066179f74b4490ef6ff4cce51619 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:ea37066179f74b4490ef6ff4cce516192021-11-18T05:41:14ZThe effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial.1549-12771549-167610.1371/journal.pmed.1000321https://doaj.org/article/ea37066179f74b4490ef6ff4cce516192010-08-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/20711481/?tool=EBIhttps://doaj.org/toc/1549-1277https://doaj.org/toc/1549-1676<h4>Background</h4>Most HIV-1-infected patients on effective antiretroviral therapy (ART) with plasma HIV-1 RNA levels below the detection limits of commercial assays have residual viremia measurable by more sensitive methods. We assessed whether adding raltegravir lowered the level of residual viremia in such patients.<h4>Methods and findings</h4>Patients receiving ART who had plasma HIV-1 RNA levels below 50 copies/mL but detectable viremia by single copy assay (SCA) were randomized to add either raltegravir or placebo to their ART regimen for 12 weeks; patients then crossed-over to the other therapy for an additional 12 weeks while continuing pre-study ART. The primary endpoint was the plasma HIV-1 RNA by SCA averaged between weeks 10 and 12 (10/12) compared between treatment groups. Fifty-three patients were enrolled. The median screening HIV-1 RNA was 1.7 copies/mL. The HIV-1 RNA level at weeks 10/12 did not differ significantly between the raltegravir-intensified (n = 25) and the placebo (n = 24) groups (median 1.2 versus 1.7 copies/mL, p = 0.55, Wilcoxon rank sum test), nor did the change in HIV-1 RNA level from baseline to week 10/12 (median -0.2 and -0.1 copies/mL, p = 0.71, Wilcoxon rank sum test). There was also no significant change in HIV-1 RNA level from weeks 10/12 to weeks 22/24 after patients crossed-over. There was a greater CD4 cell count increase from baseline to week 12 in the raltegravir-intensified group compared with the placebo group (+42 versus -44 cells/mm(3), p = 0.082, Wilcoxon rank sum test), which reversed after the cross-over. This CD4 cell count change was not associated with an effect of raltegravir intensification on markers of CD4 or CD8 cell activation in blood.<h4>Conclusion</h4>In this randomized, double-blind cross-over study, 12 weeks of raltegravir intensification did not demonstrably reduce low-level plasma viremia in patients on currently recommended ART. This finding suggests that residual viremia does not arise from ongoing cycles of HIV-1 replication and infection of new cells. New therapeutic strategies to eliminate reservoirs that produce residual viremia will be required to eradicate HIV-1 infection.<h4>Trial registration</h4>ClinicalTrials.gov NCT00515827Rajesh T GandhiLu ZhengRonald J BoschEllen S ChanDavid M MargolisSarah ReadBeatrice KallungalSarah PalmerKathy MedvikMichael M LedermanNadia AlatrakchiJeffrey M JacobsonAnn WiegandMary KearneyJohn M CoffinJohn W MellorsJoseph J EronAIDS Clinical Trials Group A5244 teamPublic Library of Science (PLoS)articleMedicineRENPLoS Medicine, Vol 7, Iss 8 (2010) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R |
| spellingShingle |
Medicine R Rajesh T Gandhi Lu Zheng Ronald J Bosch Ellen S Chan David M Margolis Sarah Read Beatrice Kallungal Sarah Palmer Kathy Medvik Michael M Lederman Nadia Alatrakchi Jeffrey M Jacobson Ann Wiegand Mary Kearney John M Coffin John W Mellors Joseph J Eron AIDS Clinical Trials Group A5244 team The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. |
| description |
<h4>Background</h4>Most HIV-1-infected patients on effective antiretroviral therapy (ART) with plasma HIV-1 RNA levels below the detection limits of commercial assays have residual viremia measurable by more sensitive methods. We assessed whether adding raltegravir lowered the level of residual viremia in such patients.<h4>Methods and findings</h4>Patients receiving ART who had plasma HIV-1 RNA levels below 50 copies/mL but detectable viremia by single copy assay (SCA) were randomized to add either raltegravir or placebo to their ART regimen for 12 weeks; patients then crossed-over to the other therapy for an additional 12 weeks while continuing pre-study ART. The primary endpoint was the plasma HIV-1 RNA by SCA averaged between weeks 10 and 12 (10/12) compared between treatment groups. Fifty-three patients were enrolled. The median screening HIV-1 RNA was 1.7 copies/mL. The HIV-1 RNA level at weeks 10/12 did not differ significantly between the raltegravir-intensified (n = 25) and the placebo (n = 24) groups (median 1.2 versus 1.7 copies/mL, p = 0.55, Wilcoxon rank sum test), nor did the change in HIV-1 RNA level from baseline to week 10/12 (median -0.2 and -0.1 copies/mL, p = 0.71, Wilcoxon rank sum test). There was also no significant change in HIV-1 RNA level from weeks 10/12 to weeks 22/24 after patients crossed-over. There was a greater CD4 cell count increase from baseline to week 12 in the raltegravir-intensified group compared with the placebo group (+42 versus -44 cells/mm(3), p = 0.082, Wilcoxon rank sum test), which reversed after the cross-over. This CD4 cell count change was not associated with an effect of raltegravir intensification on markers of CD4 or CD8 cell activation in blood.<h4>Conclusion</h4>In this randomized, double-blind cross-over study, 12 weeks of raltegravir intensification did not demonstrably reduce low-level plasma viremia in patients on currently recommended ART. This finding suggests that residual viremia does not arise from ongoing cycles of HIV-1 replication and infection of new cells. New therapeutic strategies to eliminate reservoirs that produce residual viremia will be required to eradicate HIV-1 infection.<h4>Trial registration</h4>ClinicalTrials.gov NCT00515827 |
| format |
article |
| author |
Rajesh T Gandhi Lu Zheng Ronald J Bosch Ellen S Chan David M Margolis Sarah Read Beatrice Kallungal Sarah Palmer Kathy Medvik Michael M Lederman Nadia Alatrakchi Jeffrey M Jacobson Ann Wiegand Mary Kearney John M Coffin John W Mellors Joseph J Eron AIDS Clinical Trials Group A5244 team |
| author_facet |
Rajesh T Gandhi Lu Zheng Ronald J Bosch Ellen S Chan David M Margolis Sarah Read Beatrice Kallungal Sarah Palmer Kathy Medvik Michael M Lederman Nadia Alatrakchi Jeffrey M Jacobson Ann Wiegand Mary Kearney John M Coffin John W Mellors Joseph J Eron AIDS Clinical Trials Group A5244 team |
| author_sort |
Rajesh T Gandhi |
| title |
The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. |
| title_short |
The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. |
| title_full |
The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. |
| title_fullStr |
The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. |
| title_full_unstemmed |
The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. |
| title_sort |
effect of raltegravir intensification on low-level residual viremia in hiv-infected patients on antiretroviral therapy: a randomized controlled trial. |
| publisher |
Public Library of Science (PLoS) |
| publishDate |
2010 |
| url |
https://doaj.org/article/ea37066179f74b4490ef6ff4cce51619 |
| work_keys_str_mv |
AT rajeshtgandhi theeffectofraltegravirintensificationonlowlevelresidualviremiainhivinfectedpatientsonantiretroviraltherapyarandomizedcontrolledtrial AT luzheng theeffectofraltegravirintensificationonlowlevelresidualviremiainhivinfectedpatientsonantiretroviraltherapyarandomizedcontrolledtrial AT ronaldjbosch theeffectofraltegravirintensificationonlowlevelresidualviremiainhivinfectedpatientsonantiretroviraltherapyarandomizedcontrolledtrial AT ellenschan theeffectofraltegravirintensificationonlowlevelresidualviremiainhivinfectedpatientsonantiretroviraltherapyarandomizedcontrolledtrial AT davidmmargolis theeffectofraltegravirintensificationonlowlevelresidualviremiainhivinfectedpatientsonantiretroviraltherapyarandomizedcontrolledtrial AT sarahread theeffectofraltegravirintensificationonlowlevelresidualviremiainhivinfectedpatientsonantiretroviraltherapyarandomizedcontrolledtrial AT beatricekallungal theeffectofraltegravirintensificationonlowlevelresidualviremiainhivinfectedpatientsonantiretroviraltherapyarandomizedcontrolledtrial AT sarahpalmer theeffectofraltegravirintensificationonlowlevelresidualviremiainhivinfectedpatientsonantiretroviraltherapyarandomizedcontrolledtrial AT kathymedvik theeffectofraltegravirintensificationonlowlevelresidualviremiainhivinfectedpatientsonantiretroviraltherapyarandomizedcontrolledtrial AT michaelmlederman theeffectofraltegravirintensificationonlowlevelresidualviremiainhivinfectedpatientsonantiretroviraltherapyarandomizedcontrolledtrial AT nadiaalatrakchi theeffectofraltegravirintensificationonlowlevelresidualviremiainhivinfectedpatientsonantiretroviraltherapyarandomizedcontrolledtrial AT jeffreymjacobson theeffectofraltegravirintensificationonlowlevelresidualviremiainhivinfectedpatientsonantiretroviraltherapyarandomizedcontrolledtrial AT annwiegand theeffectofraltegravirintensificationonlowlevelresidualviremiainhivinfectedpatientsonantiretroviraltherapyarandomizedcontrolledtrial AT marykearney theeffectofraltegravirintensificationonlowlevelresidualviremiainhivinfectedpatientsonantiretroviraltherapyarandomizedcontrolledtrial AT johnmcoffin theeffectofraltegravirintensificationonlowlevelresidualviremiainhivinfectedpatientsonantiretroviraltherapyarandomizedcontrolledtrial AT johnwmellors theeffectofraltegravirintensificationonlowlevelresidualviremiainhivinfectedpatientsonantiretroviraltherapyarandomizedcontrolledtrial AT josephjeron theeffectofraltegravirintensificationonlowlevelresidualviremiainhivinfectedpatientsonantiretroviraltherapyarandomizedcontrolledtrial AT aidsclinicaltrialsgroupa5244team theeffectofraltegravirintensificationonlowlevelresidualviremiainhivinfectedpatientsonantiretroviraltherapyarandomizedcontrolledtrial AT rajeshtgandhi effectofraltegravirintensificationonlowlevelresidualviremiainhivinfectedpatientsonantiretroviraltherapyarandomizedcontrolledtrial AT luzheng effectofraltegravirintensificationonlowlevelresidualviremiainhivinfectedpatientsonantiretroviraltherapyarandomizedcontrolledtrial AT ronaldjbosch effectofraltegravirintensificationonlowlevelresidualviremiainhivinfectedpatientsonantiretroviraltherapyarandomizedcontrolledtrial AT ellenschan effectofraltegravirintensificationonlowlevelresidualviremiainhivinfectedpatientsonantiretroviraltherapyarandomizedcontrolledtrial AT davidmmargolis effectofraltegravirintensificationonlowlevelresidualviremiainhivinfectedpatientsonantiretroviraltherapyarandomizedcontrolledtrial AT sarahread effectofraltegravirintensificationonlowlevelresidualviremiainhivinfectedpatientsonantiretroviraltherapyarandomizedcontrolledtrial AT beatricekallungal effectofraltegravirintensificationonlowlevelresidualviremiainhivinfectedpatientsonantiretroviraltherapyarandomizedcontrolledtrial AT sarahpalmer effectofraltegravirintensificationonlowlevelresidualviremiainhivinfectedpatientsonantiretroviraltherapyarandomizedcontrolledtrial AT kathymedvik effectofraltegravirintensificationonlowlevelresidualviremiainhivinfectedpatientsonantiretroviraltherapyarandomizedcontrolledtrial AT michaelmlederman effectofraltegravirintensificationonlowlevelresidualviremiainhivinfectedpatientsonantiretroviraltherapyarandomizedcontrolledtrial AT nadiaalatrakchi effectofraltegravirintensificationonlowlevelresidualviremiainhivinfectedpatientsonantiretroviraltherapyarandomizedcontrolledtrial AT jeffreymjacobson effectofraltegravirintensificationonlowlevelresidualviremiainhivinfectedpatientsonantiretroviraltherapyarandomizedcontrolledtrial AT annwiegand effectofraltegravirintensificationonlowlevelresidualviremiainhivinfectedpatientsonantiretroviraltherapyarandomizedcontrolledtrial AT marykearney effectofraltegravirintensificationonlowlevelresidualviremiainhivinfectedpatientsonantiretroviraltherapyarandomizedcontrolledtrial AT johnmcoffin effectofraltegravirintensificationonlowlevelresidualviremiainhivinfectedpatientsonantiretroviraltherapyarandomizedcontrolledtrial AT johnwmellors effectofraltegravirintensificationonlowlevelresidualviremiainhivinfectedpatientsonantiretroviraltherapyarandomizedcontrolledtrial AT josephjeron effectofraltegravirintensificationonlowlevelresidualviremiainhivinfectedpatientsonantiretroviraltherapyarandomizedcontrolledtrial AT aidsclinicaltrialsgroupa5244team effectofraltegravirintensificationonlowlevelresidualviremiainhivinfectedpatientsonantiretroviraltherapyarandomizedcontrolledtrial |
| _version_ |
1718424887341613056 |